Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:denosumab
|
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:FDA
2010 |
| gptkbp:ATCCode |
gptkb:M05BX04
|
| gptkbp:brand |
gptkb:denosumab
|
| gptkbp:chemicalClass |
gptkb:monoclonal_antibody
|
| gptkbp:contraindication |
hypocalcemia
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xgeva
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Amgen
|
| gptkbp:mechanismOfAction |
RANKL inhibitor
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
infections
hypocalcemia osteonecrosis of the jaw |
| gptkbp:usedFor |
prevention of skeletal-related events in patients with bone metastases from solid tumors
treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy treatment of giant cell tumor of bone |
| gptkbp:bfsParent |
gptkb:Amgen
|
| gptkbp:bfsLayer |
6
|